Related Experiment Video
Updated: Jan 23, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
[The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial
1Federal state budgetary educational institution of higher education "Rostov state medical University" of the Ministry of health of the Russian Federation.
Insights
Chronic kidney disease (CKD) significantly increases cardiovascular risks, including atrial fibrillation (AF). This review covers AF treatment in CKD patients, focusing on direct oral anticoagulants versus warfarin.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is a major risk factor for cardiovascular events.
- CKD is associated with increased risks of heart failure exacerbation, myocardial infarction, and cardiovascular mortality.
- Atrial fibrillation (AF) is a notable adverse event in patients with CKD.
Purpose of the Study:
- To discuss current therapeutic strategies for AF in patients across various stages of CKD.
- To review the benefits of specific direct oral anticoagulants (DOACs) in this population.
- To compare the efficacy and safety of DOACs with warfarin therapy.
Main Methods:
- Literature review of current treatment approaches for AF in CKD.
- Analysis of data on the benefits of DOACs in CKD patients.
- Pharmacokinetic and pharmacodynamic evaluation of DOACs in relation to CKD.
Main Results:
- DOACs offer benefits in managing AF in CKD patients.
- Comparative data suggest specific DOACs may be advantageous over warfarin.
- Understanding DOAC pharmacokinetics/pharmacodynamics is crucial for effective CKD therapy.
Conclusions:
- Treatment of AF in CKD requires careful consideration of anticoagulation strategies.
- DOACs represent a significant therapeutic option, with individualized selection based on CKD stage and drug properties.
- Further research into optimal anticoagulation in CKD is warranted.
Abstract:
Chronic kidney disease (CKD) is a powerful cardiovascular risk factor, its presence is accompanied by an increased risk of hospitalization for exacerbation of chronic heart failure (CHF), adverse outcomes in myocardial infarction, and cardiovascular mortality. Among the adverse events, an increased risk of atrial fibrillation (AF) should be noted. This article contains discussion of current approaches to the treatment of AF in patients with different stages of CKD, data on benefits of certain direct oral anticoagulants, as well as comparative characteristics of therapy with direct oral anticoagulants and warfarin. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants, which determine the features of therapy in CKD, are also considered.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Quantitative Aspects of Drug-Receptor Interaction

